Hamilton and BioFluidica Pen Next Generation Liquid Biopsy Platform Co-Marketing Agreement

September 27, 2022

Press Release Image

BioFluidica LiquidScan™ Harnesses the Power of Microfluidics

Biofluidica, Inc., and Hamilton Company, today announced a co-marketing agreement to bring advanced Liquid Biopsy capabilities to laboratories worldwide. Biofluidica has developed the next-generation liquid biopsy platform, enabling Hamilton liquid handlers (Microlab® STAR™ and STARlet™) to process biological samples to isolate extremely rare circulating tumor cells (CTCs), circulating Leukemic cells (CLCs), fetal cells, cfDNA, and exosomes. The Biofluidica platform, LiquidScan™, integrates seamlessly into the Hamilton pipetting robots. The high precision fluid control provided by the Hamilton automated pipetting channels is designed to avoid processing loss using the Biofluidica proprietary closed-loop pipetting interface with the Biofluidica microfluidic biomarker selection chips.

BioFluidica’s next-generation platform

By Jamie Reno

June 15, 2022

Asco News Article Image

BioFluidica presented its LiquidScan, a microfluidic chip that searches a blood sample for rare biomarkers such as CTCs (circulating tumor cells), cell-free DNA (cfDNA), and/or exosomes, which are particles that release naturally from a cell.

Rolf Muller, the company’s chief executive officer, noted that the technologies developed by BioFluidica can be used to determine if a person with cancer is a candidate for targeted therapy.

BioFluidica Attends and Exhibits at ASCO Annual Meeting.

June 3 - 7, 2022

Asco News Article Image

BioFluidica attended the ASCO Annual Meeting, exhibiting at Booth 21160 and presenting a poster abstract about the results of a patient sample HER2 positivity study comparing Needle Biopsy to LiquidScan. You can view the poster abstract below.

BioFluidica to Introduce Next-Generation Biomarker Isolation Platform

April 5, 2022

Biofluidica Logo

SAN DIEGO, April 5, 2022 - Biofluidica today announced they will be introducing their new biomarker isolation platform, LiquidScan™, at the annual AACR Conference on April 10-13 in New Orleans. The novel platform isolates and enriches biomarker population directly from a blood draw replacing the need for surgical biopsies and making testing available for cancer types not previously amenable to surgical biopsy.

LiquidScan harnesses the power of microfluidics to isolate and enrich the three main categories of biomarkers from whole blood: rare cells, for example circulating tumor cells (CTCs) and fetal cells, exosomes, cfDNA, as well as infectious disease agents.

BioFluidica nabs $6M in funding

By staff writers

February 10, 2022

LabPulse Logo

February 10, 2022 -- Biotechnology company BioFluidica raised more than $6 million in a recent round of financing. The San Diego-based company is developing a handheld infectious disease detection device called LiquidScan.

LiquidScan uses nanofluidics for ultrafast high-sensitivity detection of virus particles.

This latest funding round was led by BioFluidica's existing investor base, with participation from new investors, BioFluidica said. The investment supplements funding the company received from the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) initiative to develop at-home, low-cost, high-sensitivity tests for COVID-19.

BioFluidica was co-founded by Dr. Steven Soper, a foundation distinguished professor of chemistry, mechanical engineering, bioengineering, and cancer biology at Kansas University.

Ultrasound in Obstetrics and Gynecology

By Jiri Sonek

January 17, 2021

Ultrasound News Article

M.U. is a 32-year-old G2 P1 Caucasian female, who presented at 13 weeks’ gestation by LMP for first trimester combined screening. The crown-to-rump length measurement was consistent with 11 weeks’ gestation. The fetal body was noted to be small in comparison to the head and there was suspicion for ventriculomegaly. The placenta was noted to be thin. The patient was offered chorionic villus sampling (CVS) due to the increased suspicion of digynic triploidy. She declined CVS at this time but did agree to have NIPS performed. NIPS was reported as “high-risk due to low fetal DNA fr action” but was otherwise uninformative. The patient had a transcervical CVS performed two weeks later without complications.

BioFluidica Applying Liquid Biopsy to Detect Leukemia While Reducing Biopsies

genomeweb | By John Gilmore

January 17, 2019

genomeweb News Article

NEW YORK (GenomeWeb) – Fresh off being awarded several grants by the National Institutes of Health, startup BioFluidica has begun three different clinical studies to detect exosomes, cell-free DNA, and rare cells in patients' bloodstreams to identify acute lymphoblastic leukemia (ALL) and other cancer-related diseases.

The San Diego, California-based startup is also exploring the use of its Liquid Scan platform in the non-invasive prenatal testing space by extracting and detecting neonatal cells from a mother's bloodstream.

UNC Women’s Basketball Coach, Sylvia Hatchell’s Story

BioFluidica Featured on ABC News: "Liquid Biopsy Revolution"

BioFluidica Presents at AACR 2019

April 1, 2019

AACR 2019

BioFluidica presented at the AACR Conference in Atlanta, GA, April 2019 the following abstracts, "A Non-invasive Diagnostics to Detect Circulating Leukemic Cells in Blood. A microfluidic platform to monitor MRD in Leukemic patients" and "Automated Microfluidic Platform Allows for Interrogation of Tumor Biomarkers from Whole Blood."

Market Intel: Liquid Biopsy-Ready For Prime Time?

MedTech Insight|Bob Kronemyer

March 12, 2019

Detecting Undetectable Cancers

San Diego, California-based BioFluidica Inc. developed the Liquid Scan microfluidic chip that can both monitor and detect circulating tumor cells through a simple blood test.

Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA.

BioFluidica Presents at Molecular Med TRI-CON

March 10, 2019

Tri-Con 2019

BioFluidica presented at the Molecular Med Tri-Conference in San Francisco, CA, March 2019 the following abstracts, "Detection of CTCs from Whole Blood of Lung Cancer Patients Using Automated Liquid Scan Microfluidic Chip Technology" and "Isolation of Cancer Cell-Derived Extracellular Vesicles Utilizing an Automated Microfluidic Platform".

BioFluidica CoFounder and CTO, Stephen Soper, on Facebook Live: Bench to Bedside.

The University of Kansas Cancer Center

January 20, 2019

Detecting Undetectable Cancers

Tune in February 20, 2019 as KU Cancer Center director Roy Jensen, MD, will host Steven Soper, PhD, KU Cancer Center researcher and University of Kansas School of Engineering foundation distinguished professor in the departments of Chemistry and Mechanical Engineering, as well as Andrew Godwin, PhD, deputy director of KU Cancer Center. They will discuss how cancers can be detected earlier using precision medicine tools.

For more information or to sign up:

BioFluidica presents at the Prenatal Diagnostics Conference

November, 2018

NIPT Poster

BioFluidica presented at the Prenatal Diagnostics Conference in Boston, MA, November 2018 the following abstract titled "A Microfluidic Platform to Capture & Detect Trophoblastic Fetal Cells from Maternal Blood for Noninvasive Prenatal Screening".

San Diego Blood Chip Maker BioFluidica Awarded Two NIH/NCI Grants for Isolation of Cell-Free DNA and Exosomes on Its Single Liquid Biopsy Platform

PR Newswire

January 07, 2019

Isolation of DNA and Exosomes

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, has been awarded two separate SBIR Phase I NIH grants, the first in support of "Parallel and high throughput isolation of cancer cell derived extracellular vesicles," and the second in support of "Parallel and high throughput isolation of cfDNA to target detection of rare, highly conserved nucleotide polymorphisms."

"We are excited to expand our technology to be able to capture not only circulating cancer cells from solid tumor and blood cancers but also now to begin to isolate cfDNA and exosomes, as well," said Rolf Muller, BioFluidica's CEO. "We can now employ all important biomarkers on one single liquid biopsy platform, our programmable microfluidic chips. This will have very positive outcomes for personalized medicine in the cancer diagnostics space as we commercialize further, as well as for researchers and patients."

In Promise of True Liquid Biopsy for Cancer, Chip Company BioFluidica® Awarded $1.7 Million by National Cancer Institute/National Institutes of Health for Clinical Trial in Children with Acute Lymphoblastic Leukemia

PR Newswire

January 10, 2019

Money Award for Leukemia Trial

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, has been awarded an SBIR Phase II National Institutes of Health grant of $1.7 million for a clinical trial in support of "Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia."

Acute lymphoblastic leukemia (ALL) is the most common malignant disease in childhood and accounts for approximately 30% of all cancers diagnosed before the age of 18 years. The primary cause of death for ALL patients is disease relapse. Therefore, monitoring for minimal residual disease (MRD) is considered the most powerful predictor of outcome in acute leukemias.

BioFluidica turns to blood for accurate, inexpensive cancer tests

San Diego Union Tribune | By Bradley J. Fikes

August 31, 2018

News Article One

Blood is hard to beat for detecting disease. This liquid tissue circulates throughout the body, picking up chemicals, cell fragments and whole cells. But signs of disease may be exceedingly rare, and reliably picking them out has spawned an industry devoted to the task.

La Jolla’s BioFluidica says it has greatly improved upon existing technology with its own method to find circulating cancer cells. which it is testing in leukemia patients. The goal is to replace invasive and painful bone marrow biopsies for detecting when the cancer reoccurs.

In Promise of True Liquid Biopsy for Cancer, BioFluidica® Launches Human Trial for Rapid Detection of Minimal Residual Disease in Acute Myeloid Leukemia from Peripheral Blood Using high through-put automation and programmable Microfluidic Chips

PR Newswire

May 16, 2018

Leukemia Human Trials

SAN DIEGO, May 16, 2018 /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, today announced the continuation of a highly successful small patient study to replace painful bone marrow biopsies through a simple blood test for Acute Myeloid Leukemia. The larger study sponsored by a $1.5 million Phase 2 Award from Small Business Innovation Research enrolls and tracks 40 patients with Acute Myeloid Leukemia, a type of cancer of the blood and bone marrow, in a one-year pilot study to search for minimal residual disease (cancer cells undetected after treatment) and for possible onset of relapse following therapy.